$ALGS
Aligos Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022021248 Filed on November 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2021 Q3
Revenue $4.106M $1.537M
YoY Change 167.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.263M $6.473M
YoY Change -18.69% 53.03%
% of Gross Profit
Research & Development $17.79M $28.13M
YoY Change -36.76% 62.31%
% of Gross Profit
Depreciation & Amortization $500.0K $765.0K
YoY Change -34.64% 8.05%
% of Gross Profit
Operating Expenses $23.05M $34.61M
YoY Change -33.38% 60.53%
Operating Profit -$18.95M -$33.07M
YoY Change -42.7% 53.4%
Interest Expense $284.0K $20.00K
YoY Change 1320.0% -91.3%
% of Operating Profit
Other Income/Expense, Net -$182.0K $50.00K
YoY Change -464.0% -100.42%
Pretax Income -$18.66M -$33.00M
YoY Change -43.44% -0.9%
Income Tax -$43.00K $126.0K
% Of Pretax Income
Net Earnings -$18.62M -$33.12M
YoY Change -43.78% -0.52%
Net Earnings / Revenue -453.51% -2155.11%
Basic Earnings Per Share -$0.44 -$0.78
Diluted Earnings Per Share -$0.44 -$781.2K
COMMON SHARES
Basic Shares Outstanding 42.76M 42.61M
Diluted Shares Outstanding 42.76M 42.40M

Balance Sheet

Concept 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $142.3M $242.2M
YoY Change -41.24% 245.49%
Cash & Equivalents $86.44M $239.7M
Short-Term Investments $55.86M $2.451M
Other Short-Term Assets $7.709M $6.485M
YoY Change 18.87% 111.03%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $150.1M $248.7M
YoY Change -39.64% 237.44%
LONG-TERM ASSETS
Property, Plant & Equipment $5.250M $6.272M
YoY Change -16.29% -27.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $492.0K
YoY Change -100.0%
Other Assets $653.0K $748.0K
YoY Change -12.7% -73.7%
Total Long-Term Assets $13.98M $14.40M
YoY Change -2.93% -22.13%
TOTAL ASSETS
Total Short-Term Assets $150.1M $248.7M
Total Long-Term Assets $13.98M $14.40M
Total Assets $164.1M $263.1M
YoY Change -37.63% 185.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.931M $2.601M
YoY Change 12.69% -66.14%
Accrued Expenses $13.68M $22.76M
YoY Change -39.9% 132.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $138.0K $81.00K
YoY Change 70.37% -19.0%
Total Short-Term Liabilities $30.54M $34.78M
YoY Change -12.19% 74.04%
LONG-TERM LIABILITIES
Long-Term Debt $307.0K $320.0K
YoY Change -4.06% -97.82%
Other Long-Term Liabilities $133.0K $267.0K
YoY Change -50.19% -9.49%
Total Long-Term Liabilities $133.0K $267.0K
YoY Change -50.19% -9.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.54M $34.78M
Total Long-Term Liabilities $133.0K $267.0K
Total Liabilities $42.06M $46.06M
YoY Change -8.69% -0.49%
SHAREHOLDERS EQUITY
Retained Earnings -$377.2M -$265.4M
YoY Change 42.13% 89.14%
Common Stock $499.1M $482.6M
YoY Change 3.41% 13232.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $122.0M $217.0M
YoY Change
Total Liabilities & Shareholders Equity $164.1M $263.1M
YoY Change -37.63% 185.38%

Cashflow Statement

Concept 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$18.62M -$33.12M
YoY Change -43.78% -0.52%
Depreciation, Depletion And Amortization $500.0K $765.0K
YoY Change -34.64% 8.05%
Cash From Operating Activities -$17.14M -$25.37M
YoY Change -32.45% 53.1%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K -$97.00K
YoY Change -96.91% -71.47%
Acquisitions
YoY Change
Other Investing Activities $32.49M $57.00K
YoY Change 56892.98% -99.79%
Cash From Investing Activities $32.48M -$40.00K
YoY Change -81307.5% -100.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -19.00K 77.95M
YoY Change -100.02% -8305.47%
NET CHANGE
Cash From Operating Activities -17.14M -25.37M
Cash From Investing Activities 32.48M -40.00K
Cash From Financing Activities -19.00K 77.95M
Net Change In Cash 15.33M 52.54M
YoY Change -70.83% 474.88%
FREE CASH FLOW
Cash From Operating Activities -$17.14M -$25.37M
Capital Expenditures -$3.000K -$97.00K
Free Cash Flow -$17.13M -$25.27M
YoY Change -32.2% 55.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
3918000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
7709000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13526000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
150093000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
204424000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8073000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8789000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5250000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6180000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
15110000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
653000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
866000
CY2022Q3 us-gaap Assets
Assets
164069000
CY2021Q4 us-gaap Assets
Assets
235369000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2931000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3015000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13678000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25394000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3069000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2769000
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
138000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
138000
CY2022Q3 algs Deferred Revenue From Collaboration Current
DeferredRevenueFromCollaborationCurrent
10725000
CY2021Q4 algs Deferred Revenue From Collaboration Current
DeferredRevenueFromCollaborationCurrent
7641000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30541000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38957000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9652000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11287000
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
174000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
261000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
133000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
133000
CY2022Q3 algs Deferred Revenue From Collaboration Non Current
DeferredRevenueFromCollaborationNonCurrent
1556000
CY2022Q3 us-gaap Liabilities
Liabilities
42056000
CY2021Q4 us-gaap Liabilities
Liabilities
50638000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
320000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
320000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42815593
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42815593
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42690229
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42690229
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
499082000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
487347000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-377232000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-303072000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-303100000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
159000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
452000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
122013000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
184731000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
164069000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
235369000
CY2022Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
4106000
CY2021Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
1537000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
10370000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
142300000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
3992000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17791000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28132000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65977000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75555000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
38258
CY2021 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
163855
CY2022Q3 algs Aggregate Price For Share Repurchase
AggregatePriceForShareRepurchase
100000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5263000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6473000
CY2021Q4 algs Aggregate Price For Share Repurchase
AggregatePriceForShareRepurchase
300000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19291000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18810000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
23054000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
34605000
us-gaap Operating Expenses
OperatingExpenses
85268000
us-gaap Operating Expenses
OperatingExpenses
94365000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18948000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-33068000
us-gaap Operating Income Loss
OperatingIncomeLoss
-74898000
us-gaap Operating Income Loss
OperatingIncomeLoss
-90373000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18621000
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
284000
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
70000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-33124000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
795000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-44000
us-gaap Net Income Loss
NetIncomeLoss
-74160000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18664000
us-gaap Net Income Loss
NetIncomeLoss
-90618000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42761928
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32998000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42761928
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42399984
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-74103000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90417000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-43000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
126000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
57000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42399984
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42647732
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
201000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18621000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-33124000
us-gaap Net Income Loss
NetIncomeLoss
-74160000
us-gaap Net Income Loss
NetIncomeLoss
-90618000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
109000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-293000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-67000
CY2021Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-2000
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-5000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
109000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-293000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-62000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18512000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33123000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74453000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-90680000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.31
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42761928
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42761928
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42399984
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42399984
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42647732
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42647732
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39151095
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39151095
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
136981000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
3272000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
219000
CY2022Q3 algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
44000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
109000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18621000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
122013000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
184731000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
111000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
10306000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1110000
algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
188000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-293000
us-gaap Net Income Loss
NetIncomeLoss
-74160000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
122013000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
168882000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
78584000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
-727000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3295000
CY2021Q3 algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
82000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-33124000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
217011000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
220039000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
327000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
78584000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001799448
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39617
dei Entity Registrant Name
EntityRegistrantName
Aligos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4724808
dei Entity Address Address Line1
EntityAddressAddressLine1
One Corporate Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
466-6059
dei Security12b Title
Security12bTitle
Common Stock, par value, $0.0001 per share
dei Trading Symbol
TradingSymbol
ALGS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
us-gaap Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
-727000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9260000
algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
208000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-62000
us-gaap Net Income Loss
NetIncomeLoss
-90618000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
217011000
us-gaap Net Income Loss
NetIncomeLoss
-74160000
us-gaap Net Income Loss
NetIncomeLoss
-90618000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
84000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-63000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
994000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
474000
us-gaap Depreciation
Depreciation
1784000
us-gaap Depreciation
Depreciation
2291000
us-gaap Share Based Compensation
ShareBasedCompensation
11277000
us-gaap Share Based Compensation
ShareBasedCompensation
9806000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-6167000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
259000
algs Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
278000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-84000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-712000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-11528000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5861000
algs Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1334000
algs Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-985000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-111000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4640000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3992000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62606000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78182000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
42695000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
13000000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
79740000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
1961000
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
982000
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
10000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
852000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
556000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37897000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19501000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
78584000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
111000
algs Payments On Deferred Offering Costs
PaymentsOnDeferredOfferingCosts
727000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
88000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
59000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
327000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
78125000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-100460000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
19444000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186980000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
220943000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86520000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
240387000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86440000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
239734000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
80000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
653000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86520000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
240387000
algs Market To Market Adjustments For Available For Sale Investments
MarketToMarketAdjustmentsForAvailableForSaleInvestments
-293000
algs Market To Market Adjustments For Available For Sale Investments
MarketToMarketAdjustmentsForAvailableForSaleInvestments
-67000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
459000
algs Vesting Of Early Exercised Options Value
VestingOfEarlyExercisedOptionsValue
189000
algs Vesting Of Early Exercised Options Value
VestingOfEarlyExercisedOptionsValue
208000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86440000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
186816000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
80000
algs Change In Pension Obligation
ChangeInPensionObligation
5000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
164000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
55864000
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aligos Therapeutics, Inc. (Aligos-US) was incorporated in the state of Delaware on February 5, 2018 (inception). On September 10, 2018, the Company formed Aligos Belgium BVBA (Aligos-Belgium), a limited liability company organized under the laws of Belgium. On March 30, 2020, the Company formed as a wholly owned subsidiary, Aligos Australia Pty LTD (Aligos-Australia), a proprietary limited company. On May 18, 2021, the Company formed as a wholly owned subsidiary, Aligos Therapeutics (Shanghai) Co. Ltd. (Aligos-Shanghai) and together with Aligos-US, Aligos-Belgium, and Aligos-Australia being the “Company” or “Aligos”.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aligos is a clinical-stage biopharmaceutical company developing novel therapeutics to address unmet medical needs in viral and liver diseases, including for chronic hepatitis B, coronaviruses and non-alcoholic steatohepatitis (NASH).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is devoting substantially all of its efforts to the research and development of its drug candidates. The Company has not generated any product revenue to date. The Company is also subject to a number of risks similar to other companies in the biotechnology industry, including the uncertainty of success of its nonclinical studies and clinical trials, regulatory approval of drug candidates, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third-parties, product liability, and dependence on key individuals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial public offering</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 20, 2020, the Company closed its initial public offering (IPO) at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions. On November 5, 2020, the underwriters of the IPO partially exercised their overallotment, resulting in an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and commissions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred losses and negative cash flows from operations since its inception. As of September 30, 2022 and December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">377.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">303.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of expanded research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, the Company has unrestricted cash, cash equivalents and investments of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which is available to fund future operations. The Company expects to continue to spend substantial amounts to continue the nonclinical and clinical development of its current and future programs. If the Company is able to gain marketing approval for drug candidates that are being developed, it will require significant additional amounts of cash in order to launch and commercialize such drug candidates. In addition, other unanticipated costs may arise. Because the design and outcome of the Company’s planned and anticipated clinical trials is highly uncertain, the Company cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any drug candidate the Company may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expects to finance its cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. In addition, the Company may seek additional capital to take advantage of favorable market conditions or strategic opportunities even if the Company believes it has sufficient funds for its current or future operating plans. Based on the Company’s research and development plans, the Company expects its existing unrestricted cash, cash equivalents and investments, will enable it to fund its operations for at least 12 months following the date the condensed consolidated financial statements are issued. However, the Company’s operating plan may change as a result of many factors currently unknown, and the Company may need to seek additional funds sooner than planned. Moreover, it is particularly difficult to estimate with certainty the Company’s future expenses given the dynamic nature of its business, the COVID‑19 pandemic and the macro-economic environment generally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond its control. For example, the COVID-19 pandemic, the current inflationary economic environment and rising interest rates have resulted in a disruption of global financial markets. If the disruption persists or deepens, the Company could be unable to access additional capital, which could negatively affect its ability to consummate certain corporate development transactions or other important, beneficial or opportunistic investments. If additional funds are not available to the Company when needed, on terms that are acceptable to the Company, or at all, the Company may be required to: delay, limit, reduce or terminate nonclinical studies, clinical trials or other research and development activities or eliminate one or more of its development programs altogether; or delay, limit, reduce or terminate its efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize any future approved products, or reduce the Company’s flexibility in developing or maintaining its sales and marketing strategy.</span></p>
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-377200000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14296000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13442000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9046000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7262000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5250000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6180000
CY2022Q3 us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
1800000
CY2021Q3 us-gaap Depreciation
Depreciation
800000
us-gaap Depreciation
Depreciation
2300000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
19068000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
40000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
19028000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42647732
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39151095
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39151095
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
56197000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
55864000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
56197000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
55864000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5070000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6329000
CY2022Q3 algs Accrued Payables Current
AccruedPayablesCurrent
7609000
CY2021Q4 algs Accrued Payables Current
AccruedPayablesCurrent
17554000
CY2022Q3 algs Liability For Early Exercised Stocks Options Current
LiabilityForEarlyExercisedStocksOptionsCurrent
87000
CY2021Q4 algs Liability For Early Exercised Stocks Options Current
LiabilityForEarlyExercisedStocksOptionsCurrent
276000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
912000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1235000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13678000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25394000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3491000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3592000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11277000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9806000
CY2022Q3 algs Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
0
algs Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
0
CY2021Q3 algs Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
0
algs Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
0
CY2022Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.31
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10082266
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5775537
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10082266
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5775537

Files In Submission

Name View Source Status
0000950170-22-021248-index-headers.html Edgar Link pending
0000950170-22-021248-index.html Edgar Link pending
0000950170-22-021248.txt Edgar Link pending
0000950170-22-021248-xbrl.zip Edgar Link pending
algs-20220930.htm Edgar Link pending
algs-20220930.xsd Edgar Link pending
algs-ex31_1.htm Edgar Link pending
algs-ex31_2.htm Edgar Link pending
algs-ex32_1.htm Edgar Link pending
algs-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
algs-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
algs-20220930_lab.xml Edgar Link unprocessable
algs-20220930_cal.xml Edgar Link unprocessable
algs-20220930_htm.xml Edgar Link completed
algs-20220930_def.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending